Immunity to Measles, Mumps, and Rubella in US Children with Perinatal HIV Infection or Perinatal HIV Exposure Without Infection

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 988-995

  Siberry, George K ^a   Patel, Kunjal ^b   Bellini, William J ^c   Karalius, Brad ^b   Purswani, Murli U ^d   Burchett, Sandra K ^e   Meyer, William A ^f   Sowers, Sun Bae ^c   Ellis, Angela ^g   Van Dyke, Russell B ^h  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d BRONX LEBANON HOSPITAL CENTER   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunity; measles; mumps; perinatal HIV; rubella

Indexed keywords

MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; ENVIRONMENTAL EXPOSURE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MUMPS; PERINATAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RUBELLA; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; SERODIAGNOSIS; UNITED STATES; VIRAL PLAQUE ASSAY;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEASLES; MUMPS; NEUTRALIZATION TESTS; RUBELLA; UNITED STATES; VIRAL PLAQUE ASSAY;

EID: 84940703525     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ440     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013. summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62(No. RR-4):1-34.
2. Papania MJ, Wallace GS, Rota PA, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr 2014; 168:148-55.
3. Orenstein W, Seib K. Mounting a good offense against measles. N Engl J Med 2014; 371:1661-3.
4. Centers for Disease Control and Prevention. Measles cases and outbreaks. Available at: http://www.cdc.gov/measles/cases-outbreaks.html. Accessed 3 November 2014.
5. Centers for Disease Control and Prevention. Mumps cases and outbreaks. Available at: http://www.cdc.gov/mumps/outbreaks.html. Accessed 3 November 2014.
6. Albertyn C, van der Plas H, Hardie D, et al. Silent casualties from the measles outbreak in South Africa. S Afr Med J 2011; 101:313-4, 316-7.
7. le Roux DM, le Roux SM, Nuttall JJ, Eley BS. South African measles outbreak 2009-2010 as experienced by a paediatric hospital. S Afr Med J 2012; 102:760-4.
8. Moss WJ, Fisher C, Scott S, et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis 2008; 46:523-7.
9. Centers for Disease Control and Prevention. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection. MMWR Morb Mortal Wkly Rep 1996; 45:603-6.
10. Van Dyke RB, Patel K, Siberry GK, et al. Pediatric HIV/AIDS Cohort Study. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr 2011; 57:165-73.
11. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10:630-42.
12. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17):1-19.
13. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43(RR-12):1-10.
14. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000; 314:1-27.
15. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
16. Cohen BJ, Audet S, Andrews N, Beeler J;WHO working group onmeasles plaque reduction neutralization test. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66.
17. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007; 196:1459-64.
18. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006; 43(suppl 3):S146-50.
19. Abzug MJ, Qin M, Levin MJ, et al. International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2012; 206:512-22.
20. Zinna SS, Bamford A, Cunnington A, et al. Immunization status of children with HIV: failure to protect a vulnerable population. HIV Med 2011; 12:447-8.
21. Schulte JM, Burkham S, Squires JE, et al. Immunization status of children born to human immunodeficiency virus (HIV)-infected mothers in two Texas cities. South Med J2000; 93:48-52.
22. Succi RC, Krauss MR, Harris DR, et al. NISDI Pediatric Study Group 2012. Undervaccination of perinatally HIV-infected and HIV-exposed uninfected children in Latin America and the Caribbean. Pediatr Infect Dis J 2013; 32:845-50.
23. Kidzeru EB, Hesseling AC, Passmore JA, et al. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. AIDS 2014; 28:1421-30.
24. Abramczuk BM, Mazzola TN, Moreno YM, et al. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol 2011; 18:1406-9.
25. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4.
26. Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virusspecific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-8.
27. Farquhar C,Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre-and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-9.
28. Lima M, De Menezes Succi RC, Nunes Dos Santos AM, Weckx LY, De Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004; 23:604-7.
29. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006; 7:467-70.
30. Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Swiss Mother and Child HIV Cohort Study of Switzerland. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virusinfected children living in Switzerland. Clin Vaccine Immunol 2012; 19: 1751-7.
31. Siberry GK, Williams PL, Lujan-Zilbermann J, et al. IMPAACT P1065 Protocol Team. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010; 29:391-6.
32. Madhi SA, Adrian P, Cotton MF, et al. Comprehensive International Program of Research on AIDS 4 Study Team. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202:355-61.
33. Centers for Disease Control and Prevention. HIV surveillance report, 2011; 23:52-53.
34. Simani OE, Izu A, Violari A, et al. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. AIDS 2014; 28:531-41.
35. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA. 2009; 106:7939-44.
36. Haralambieva IH, Salk HM, Lambert ND, et al. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine 2014; 32:1946-53.